RFA-AI-25-013: Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trials Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2025.
National Institutes of Health offered grants to colleges and universities. Applications closed on November 7, 2025.
From the official notice on Grants.gov, last changed September 18, 2025. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUC7
- Clinical trialsNot allowed
- Funded byNIAID
- Median yearly award$1.9 million
- Typical project length18.5 years
Projects funded under RFA-AI-25-013 were run by National Institute of Allergy and Infectious Diseases (NIAID, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AI-25-013 in the NIH Guide.
Key dates
| Posted | September 18, 2025 |
|---|---|
| Deadline | November 7, 2025 |
| Archived by Grants.gov | December 13, 2025 |
Who can apply
This opportunity was open to colleges and universities.
- Public and State controlled institutions of higher education
- Private institutions of higher education
Other Eligible Applicants include the following: Eligible Organizations: The University of Texas Medical Branch at Galveston, TX and Boston University, Boston, MA Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The goal of this notice of funding opportunity (NOFO) is to continue to provide operations support to the National Biocontainment Laboratories at the University of Texas Medical Branch (UTMB) in Galveston, Texas and Boston University in Boston, Massachusetts. Operations support is provided in the following areas: facility maintenance and operations; biosecurity; environmental health and safety regulations and requirements; regulatory compliance; and specialized research support services. The NBLs serve as a national resource for efforts in conducting pre-clinical and laboratory (in vitro and in vivo) research and testing on hazardous biological agents in support of NIAIDs biodefense and emerging infectious diseases research efforts. Additionally, in times of a national biodefense or emerging infectious disease (EID) emergency, the NBLs may be expected to rapidly realign their activities to assist response efforts within the US under the direction of NIAID.
Funded under RFA-AI-25-013 so far
NIH funded 2 projects under RFA-AI-25-013 in fiscal 2026, at 2 institutions. The median yearly award was $1.9 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Boston University National Emerging Infectious Diseases Laboratories | Boston University Medical Campus | 2026 | $11.5 million |
| Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trials Not Allowed) | University of Texas Med BR Galveston | 2026 | $11.5 million |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AI-25-013 still open?
No. It closed on November 7, 2025.
Who can apply for Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trials Not Allowed)?
National Institutes of Health accepted applications from colleges and universities. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trials Not Allowed)?
Closed November 7, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-AI-25-013?
NIH RePORTER lists 2 projects funded under RFA-AI-25-013 in fiscal 2026, at 2 institutions. The most were at Boston University Medical Campus, University of Texas Med BR Galveston.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)